As a Life Science recruiter or hiring manager, knowing exactly what your target audience of jobseekers are looking for in their next role is essential in order to attract and engage top talent.
GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
A new report[1] by stakeholder intelligence firm alva has revealed the leaders in the multibillion-pound pharma industry when it comes to Equality, Diversity and Inclusion (EDI). Post-pandemic, EDI is becoming a strategic imperative for pharma organisations. Whilst several leading global organisations lead the way with their approach to EDI, some work is still needed from other organisations to shift the focus internally to achieve global diversity aims.
As a Life Science employer/recruiter, you must take steps to avoid discrimination across your entire recruitment journey, including in how you present your job adverts.
NEW YORK & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). The acquisition complements and further enhances Pfizer’s more than 30-year heritage in rare hematology and reinforces the company’s commitment to SCD by bringing expertise and a leading portfolio and pipeline with the potential to address the full spectrum of critical needs in this underserved community. Pfizer intends to continue to build on the companies’ shared commitment to and engagement with the SCD community.
– Acquisition Provides Gilead with MiroBio’s Pipeline of Immune Checkpoint Agonists and Proprietary Discovery Platform –
$76 million investment increases the site’s capacity to produce critical raw materials used in the development and manufacturing of vaccines and biologic therapies
Assure Infusions will open 60,000-square-foot advanced robotics plant in Bartow
PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched today with a $122 million oversubscribed Series A financing. The financing was led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Inspired by a few curative combination regimens in cancer and the successful drug cocktails engineered in other disease areas such as cystic fibrosis and antivirals, IDRx was incubated by Borisy Labs to address the limitations of today’s precision cancer medicines with highly selective, purposely designed drug combinations to help more patients achieve prolonged, durable responses to therapy earlier in the course of their disease.
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 28, 2022-- Labcorp (NYSE: LH) (the “Company”), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly owned Clinical Development business to Labcorp shareholders through a tax-free transaction. The planned spin-off will result in two independent, publicly traded companies, each poised for strong, sustainable growth:
